Dublin, Feb. 13, 2017 -- Research and Markets has announced the addition of the "Handheld Devices for High Viscosity Injectables" report to their offering.
Growth in high viscosity drugs is being driven by advances in biotechnology and host-vector engineering - advances that have led to a steady stream of biologics for a number of ailments and conditions. These powerful drugs come with a high cost-per-dose and the risk of significant side effects - factors that place an elevated emphasis on administration efficiency, safety and reliability.
Many drugs in this class are characterized by physical properties and sensitivities that challenge the drug commercialization ecosystem. For example, monoclonal antibodies, perhaps the most significant category in terms of therapeutic and commercial importance, typically possess viscosities that are well above the normal limits of subcutaneous injection devices and techniques.
Without a technical solution, these high viscosity drugs are formulated and supplied for infusion, a trend that threatens to put additional pressure on patient logistics and healthcare economics. Drug developers and device designers are increasingly working in collaboration to address the goal of subcutaneous administration of high viscosity injectables.
Handheld Devices for High Viscosity Injectables - What You Will Learn
- What are the markets for therapeutic drugs with viscosities that cannot be delivered using standard self-injection devices and techniques?
- What are the technologies and devices that are aimed at positioning high viscosity drugs for subcutaneous injection?
- What are the design factors, material selection issues, formulation factors, and device capabilities and limitations of handheld devices that address the limitations of high viscosity drugs?
- Who are the high viscosity injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations?
- What are the key therapeutic sectors for high viscosity injectables?
- What does the market for high viscosity injectables look like today? What will it be in 2020?
- What is the impact of economic, technology, and regulatory factors on high viscosity drugs that can be administered via handheld devices?
Key Topics Covered:
1. Executive Summary
2. The Market Opportunity
3. High Viscosity Drug Market Dynamics
- The Economics of Drug Delivery
- Market Drivers
- Growth of Biological Drugs
- Demographics and Disease Prevalence
- Innovation in Handheld Devices
- Managed Care and Healthcare Economics
- Competitive Landscape
- Risk Factors
4. High Viscosity Injection Devices - Design Factors
- Drug Properties
- Drug Storage Requirements
- Baseline Device Capabilities
- Primary Packaging
- Human Engineering/Ergonomics
- Formulation Technology
5. High Viscosity Drugs - Addressable Markets
- Legacy Drugs - IV-to-Subcutaneous Migration
- Biologicals
- Drugs Currently Approved for Infusion
- Development-stage Biologicals
- Formulation-related High Viscosity
- Sustained Release Injectables
- Solubility-enhanced Formulations
6. Analysis of High Viscosity-Capable Handheld Devices
- Specialty Glass Syringes
- Specialty Autoinjectors
- Cyclic Olefin Prefillable Syringes
- Formulation-specific Devices
7. Near-term Therapeutic Sector Analysis
- Therapy Sectors
- Forecasts and Prospects
8. Market Factors
- Regulatory Issues
- Device Branding
- Quality by Design
- Ease of Use
9. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/km5gv3/handheld_devices
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables


Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 



